As Alzheimer's Disease Cases Rise, New Report Warns of Growing Gaps in Care

A Pat Summitt Foundation white paper warns that specialist shortages, delayed diagnoses and access barriers could keep patients from benefiting from emerging Alzheimer’s treatments. It cites 7.4 million Americans age 65 and older living with Alzheimer’s in 2025, a figure expected to double by 2050, and specialty appointment waits of nine to 12 months or longer. The report also estimates that 12 million-plus caregivers provided 19.6 billion unpaid care hours in 2025, valued at approximately $446 billion; it calls for expanded specialist capacity, earlier detection and stronger caregiver support.

Analysis

The investable signal is a constraint on commercialization, not a fresh estimate of disease burden. For disease-modifying drugs such as Leqembi and Kisunla, specialist capacity, timely diagnosis, infusion access and MRI monitoring all sit between clinical eligibility and realized revenue. If those bottlenecks bind, uptake can lag optimistic penetration assumptions even as underlying need rises; capacity expansion, however, could create a multi-year runway rather than eliminate demand. The same bottleneck may favor health systems and diagnostic providers able to coordinate memory clinics, biomarker testing and monitoring, but reimbursement and incremental staffing costs determine whether added volume converts to profit.

Near term, this is a low-information advocacy report, not a catalyst: the cited physician survey is from 2020, and the release supplies no updated workforce, treatment-access or reimbursement data. Avoid extrapolating the caregiver burden into near-term revenue for any one company. Over 1–3 months, monitor drug-company disclosures for eligible-patient starts, treatment discontinuation, infusion capacity and access by geography; over 6–18 months, watch standardized blood-biomarker guidance, Medicare coverage, specialist hiring and clinic capacity. A downside path is safety concerns, restrictive coverage or weak persistence; an upside path is easier screening and care delivery that expands the treatable pool. The contrarian point: the market may focus on the large unmet need while underweighting the care-delivery bottleneck, but this release does not establish its size or justify a directional trade.

Key Decisions for Investors

• No trade on the report alone. Treat it as a reminder to haircut near-term Alzheimer’s drug adoption assumptions for access constraints, not as evidence that sales estimates should be revised today.
• For exposure to Leqembi or Kisunla, track quarterly treatment starts, persistence, MRI/infusion capacity and payer coverage before adding; a sustained acceleration in starts without rising access friction would weaken the bottleneck thesis.
• Watch health systems and diagnostic providers with demonstrable memory-care, biomarker-testing and monitoring capacity as potential relative beneficiaries; verify reimbursement, staffing costs and utilization before taking exposure.
• Falsification/watch items: updated specialist-access data showing materially improved appointment availability, broader standardized blood-biomarker guidance, or disclosed acceleration in treatment uptake. Conversely, tighter coverage, adverse safety developments or persistently slow starts would reinforce the adoption-risk view.